Covered recipient · General Payments record
CHARLES F LOVELL
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$737.64
35 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $737.64 | 35 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $253.82 | 11 |
| Novartis Pharmaceuticals Corporation | $114.29 | 3 |
| Novo Nordisk Inc | $88.98 | 5 |
| Corcept Therapeutics | $81.63 | 5 |
| Lilly USA, LLC | $65.50 | 4 |
| AstraZeneca Pharmaceuticals LP | $35.18 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $33.19 | 2 |
| PFIZER INC. | $27.38 | 1 |
| Esperion Therapeutics, Inc. | $20.63 | 1 |
| Janssen Pharmaceuticals, Inc | $17.04 | 1 |
Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHARLES F LOVELL
NPI 1174629448 · CMS profile ID 325880
Allopathic & Osteopathic Physicians / Internal Medicine
NORFOLK, VA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1174629448?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174629448?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174629448?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1174629448?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
35 matching records · $737.64 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–35 of 35.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.48 | 12/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887762655 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 12/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887762657 | CMS |
| Novartis Pharmaceuticals Corporation | $20.56 | 11/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893911563 | CMS |
| Lilly USA, LLC | $19.54 | 11/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917939855 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.13 | 10/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887356103 | CMS |
| Lilly USA, LLC | $14.22 | 10/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917941725 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.56 | 09/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887762659 | CMS |
| Janssen Pharmaceuticals, Inc | $17.04 | 09/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886967685 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7.93 | 08/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887762661 | CMS |
| Novo Nordisk Inc | $17.97 | 08/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899357541 | CMS |
| Corcept Therapeutics | $17.94 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 948779347 | CMS |
| PFIZER INC. | $27.38 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949228543 | CMS |
| Corcept Therapeutics | $17.94 | 07/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 948779307 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.48 | 07/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915054475 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.86 | 07/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887762663 | CMS |
| Lilly USA, LLC | $14.93 | 06/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917940643 | CMS |
| Novo Nordisk Inc | $16.18 | 06/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899156987 | CMS |
| Corcept Therapeutics | $15.25 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 948779283 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.94 | 06/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887762665 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11.73 | 05/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887385363 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.70 | 05/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914674091 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $73.39 | 05/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887762653 | CMS |
| Esperion Therapeutics, Inc. | $20.63 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947268333 | CMS |
| Corcept Therapeutics | $15.25 | 05/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 948779235 | CMS |
| Novo Nordisk Inc | $19.37 | 05/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899156995 | CMS |
| Novartis Pharmaceuticals Corporation | $74.04 | 05/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893911555 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.85 | 03/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887762667 | CMS |
| Corcept Therapeutics | $15.25 | 03/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 948779181 | CMS |
| Lilly USA, LLC | $16.81 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917942605 | CMS |
| Novartis Pharmaceuticals Corporation | $19.69 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893911559 | CMS |
| Novo Nordisk Inc | $19.88 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899295075 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.82 | 03/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929998477 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.37 | 02/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930228977 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.10 | 01/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887762549 | CMS |
| Novo Nordisk Inc | $15.58 | 01/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898676791 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $262,318.22 | 41 |
| PY2024 | Principal investigator | $226,779.68 | 27 |
| PY2023 | Principal investigator | $241,422.11 | 79 |
| PY2022 | Principal investigator | $283,192.02 | 266 |
| PY2021 | Principal investigator | $197,651.91 | 425 |
| PY2020 | Principal investigator | $248,697.42 | 325 |
| PY2019 | Recipient | $12,988.10 | 1 |
| PY2019 | Principal investigator | $359,002.06 | 260 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
79 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,904.47 | 12/31/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio | No dispute reported | 06/30/2026 | 991128929 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 12/29/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007778229 |
| Principal investigator 1 | ModernaTX, Inc. | $151.20 | 12/20/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259901 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,595.00 | 12/19/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | A randomized, controlled, multicenter, open-label trial comparing a post-discharge care pathway involving aggressive LDL-C management with inclisiran with usual care in patients with a recent acute coronary syndrome | No dispute reported | 06/30/2026 | 1017199493 |
| Principal investigator 1 | Novo Nordisk AS | $2,783.27 | 12/18/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1008961153 |
| Principal investigator 1 | ModernaTX, Inc. | $302.40 | 12/06/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259903 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 11/30/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007151115 |
| Principal investigator 1 | Novo Nordisk AS | $20,661.40 | 11/29/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1008164641 |
| Principal investigator 1 | Novo Nordisk AS | $7,000.06 | 11/27/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1008961135 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 11/03/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1008164627 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 10/31/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007151103 |
| Principal investigator 1 | ModernaTX, Inc. | $1,291.68 | 10/25/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259883 |
| Principal investigator 1 | ModernaTX, Inc. | $1,852.92 | 10/06/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259881 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 09/29/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007151079 |
| Principal investigator 1 | Novo Nordisk AS | $1,168.02 | 09/25/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1008164613 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 09/22/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1008164599 |
| Principal investigator 1 | Novo Nordisk AS | $1,761.20 | 09/22/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1008961101 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,438.31 | 09/15/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio | No dispute reported | 06/30/2026 | 991135079 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 08/31/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007151091 |
| Principal investigator 1 | ModernaTX, Inc. | $4,181.76 | 08/18/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259837 |
| Principal investigator 1 | Novo Nordisk AS | $5,657.04 | 08/18/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1008164583 |
| Principal investigator 1 | Novo Nordisk AS | $673.32 | 08/18/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1008961085 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 08/18/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1008961117 |
| Principal investigator 1 | Novo Nordisk AS | $3,162.50 | 08/04/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1008164569 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 07/31/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007151067 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/27/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007796985 |
| Principal investigator 1 | Novo Nordisk AS | $898.02 | 07/26/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1008164555 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/25/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007796993 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 07/18/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007796977 |
| Principal investigator 1 | ModernaTX, Inc. | $1,776.60 | 07/12/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259835 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/07/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007796969 |
| Principal investigator 1 | Novo Nordisk AS | $2,977.14 | 07/03/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9924-4635 | No dispute reported | 06/30/2026 | 1008311853 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/02/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925759 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 06/30/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007151043 |
| Principal investigator 1 | Novo Nordisk AS | $9.99 | 06/30/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007822209 |
| Principal investigator 1 | Novo Nordisk AS | $218.30 | 06/30/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007822215 |
| Principal investigator 1 | Novo Nordisk AS | $7.49 | 06/30/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925783 |
| Principal investigator 1 | Novo Nordisk AS | $709.31 | 06/23/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007822229 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/16/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925771 |
| Principal investigator 1 | Novo Nordisk AS | $46.12 | 06/13/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925777 |
| Principal investigator 1 | ModernaTX, Inc. | $6,106.26 | 06/07/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259833 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 05/31/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007151055 |
| Principal investigator 1 | Novo Nordisk AS | $709.31 | 05/26/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007822223 |
| Principal investigator 1 | Novo Nordisk AS | $10,472.76 | 05/26/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1008164541 |
| Principal investigator 1 | Novo Nordisk AS | $20.10 | 05/12/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1006778161 |
| Principal investigator 1 | ModernaTX, Inc. | $3,611.58 | 05/03/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259815 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 04/28/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007151029 |
| Principal investigator 1 | Novo Nordisk AS | $1,917.02 | 04/26/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007797003 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,069.40 | 04/25/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | A randomized, controlled, multicenter, open-label trial comparing a post-discharge care pathway involving aggressive LDL-C management with inclisiran with usual care in patients with a recent acute coronary syndrome | No dispute reported | 06/30/2026 | 1017199681 |
| Principal investigator 1 | Novo Nordisk AS | $1,797.84 | 04/24/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1006778173 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,006.58 | 03/31/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1017199241 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 03/31/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007132631 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,846.81 | 03/30/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension | No dispute reported | 06/30/2026 | 1017199003 |
| Principal investigator 1 | ModernaTX, Inc. | $3,094.20 | 03/29/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259813 |
| Principal investigator 1 | Novo Nordisk AS | $5,129.46 | 03/24/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1006778149 |
| Principal investigator 1 | Novo Nordisk AS | $414.57 | 03/24/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925745 |
| Principal investigator 1 | Novo Nordisk AS | $41.26 | 03/02/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9924-4635 | No dispute reported | 06/30/2026 | 1007238701 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 02/28/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007132615 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 02/28/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9924-4635 | No dispute reported | 06/30/2026 | 1008311839 |
| Principal investigator 1 | ModernaTX, Inc. | $2,770.20 | 02/24/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259811 |
| Principal investigator 1 | Novo Nordisk AS | $772.92 | 02/24/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9924-4635 | No dispute reported | 06/30/2026 | 1007238689 |
| Principal investigator 1 | Novo Nordisk AS | $1,404.54 | 02/22/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1006778137 |
| Principal investigator 1 | Novo Nordisk AS | $1,027.97 | 02/22/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925739 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/17/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925765 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 01/31/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4801 | No dispute reported | 06/30/2026 | 1007132597 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 01/31/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9924-4635 | No dispute reported | 06/30/2026 | 1007238711 |
| Principal investigator 1 | Novo Nordisk AS | $79.92 | 01/30/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925733 |
| Principal investigator 1 | ModernaTX, Inc. | $2,142.72 | 01/27/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042259809 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $31,590.01 | 01/27/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease | No dispute reported | 06/30/2026 | 1006165685 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $37,615.13 | 01/26/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1017198949 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 01/26/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1008258851 |
| Principal investigator 1 | Novo Nordisk AS | $5,036.04 | 01/25/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1006778123 |
| Principal investigator 1 | Novo Nordisk AS | $2,602.40 | 01/25/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925751 |
| Principal investigator 1 | Novo Nordisk AS | $2,275.20 | 01/25/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9924-4635 | No dispute reported | 06/30/2026 | 1008311825 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 01/24/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1008258865 |
| Principal investigator 1 | Novo Nordisk AS | $11.64 | 01/23/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | EX9536-4388 | No dispute reported | 06/30/2026 | 1006778111 |
| Principal investigator 1 | Amgen Inc. | $771.00 | 01/21/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH LLC | P0 ASCVD Olpasiran Prescreening for CVOT | No dispute reported | 06/30/2026 | 1029651463 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,564.15 | 01/15/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1017199555 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 01/06/2023 | Non-covered Recipient Entity YORK CLINICAL RESEARCH, LLC | NN9535-4321 | No dispute reported | 06/30/2026 | 1007925727 |